Introduction
Furin is a mammalian subtilisin/Kex2p-like endoprotease which is involved in the processing of many precursor proteins (reviewed in 1, 2, 3). The enzyme has a ubiquitous tissue distribution and cycles between the trans-Golgi network, the cell surface and the endosomes. Furin plays a role in embryogenesis and homeostasis (4) and is also responsible for processing bacterial toxin precursors and virus envelope glycoprotein precursors (5, 6) . Because of its involvement in bacterial and viral pathogenesis, furin represents an attractive target for therapeutic drugs.
Polyarginines are known to be potent, small inhibitors of furin; L6R (hexa-L-arginine), for example, exhibits the low inhibition constant (K i ) of 114 nM (7) , and the D-forms of these polyarginines were also shown to be inhibitory. Moreover D6R amide has been shown to block the activation of Pseudomonas aeruginosa exotoxin A (8) and to protect against anthrax toxemia both in vivo and in vitro (9) .
The structure of mouse furin has been recently determined (10) and reveals that the enzyme's active site contains an extended substrate-binding groove which is lined with many negatively charged residues: these include D258 and D306 (surrounding the S1 subsite); D154 and D191, which form the surface of the S2 pocket; E236 and E264 (S4 subsite); E257 and D264 (D264 takes part in forming the S4 and S5 subsites); and E230 and D233 (S6 subsite). No basic residues are present in the general area between the S5 and S1 subsites; basic residues (R193, H364 and R197) are found only on the outer edge of the S1' subsite. The highly acidic character of the substrate-binding groove explains the high inhibitory potency of positively charged polyargininecontaining peptides.
In the work described here we present the further study of the inhibitory features of polyarginines against human furin. We attempted to gain information on the positioning of D6R amide within the furin substrate binding pocket. We also scanned decapeptide libraries in search of a highly inhibitory sequence, and tested how length and terminal modification can influence the inhibitory potency of D-arginine-containing peptides. library and the individual compounds were synthesized using simultaneous multiple peptide synthesis methodology as described previously (7) .
Materials and Methods

Materials
Concentration of peptides -Although the peptides used in this study were over 99% pure, these highly basic peptides consisted of more than half salt (trifluoroacetate) and water; the actual molar concentration was thus smaller than expected. The amount of peptide in each stock was determined by quantitative amino acid analysis at the Microchemical Facility at the Winship Cancer Institute (Atlanta, GA). Using amino acid analysis, D6R amide, D7R amide, D8R amide and D9R amide were shown to contain 36%, 36%, 48% and 31% (w/w) respectively of actual peptide. Unless otherwise stated (in the figure legends) we here report peptide concentrations taking the required correction into account. Where the actual amino acid composition is not known (i. e. the peptides described in Figure 2 and Figure 5 ), this correction has not been made.
Human furin preparation -The pCMV-Fur_S vector containing cDNA encoding truncated human furin was obtained from J. W. Creemers (11) . CHO K1 cells were stably transfected and expression amplified using the DHFR-coupled amplification method as described previously (12) . The method described for mouse furin purification (7) was used for purification of human furin from conditioned media.
PACE4 preparation -Conditioned medium containing PACE4 was obtained from stably transfected HEK293 cells (13) as described previously (7) . One liter of medium was diluted three times with buffer A (20 mM HEPES pH 7.4, 0.1% Brij 35), loaded on a 5 ml Econo-Pac ® anion exchange cartridge (Bio-Rad), and eluted using a linear gradient of 0-0.5 M NaCl in 45 min. The flow rate was 1 ml/min and 1 ml fractions were collected.
Enzyme assays -The assay for furin was performed at pH 7.0 in 100 mM HEPES, 5 mM CaCl2, and 0.1% Brij 35. The substrate and enzyme concentration unless otherwise stated were 200 µM and 15 nM, and the total assay volume was 50 µl. Inhibitory peptides were preincubated with enzyme for 30 min at 37°C prior to addition of substrate. All assays were performed either in duplicate or triplicate. Inhibition constants were determined as in (14) and the equation Following this normalization, the means from five independent experiments could be calculated.
Cell culture and cytotoxicity assay -The inhibitory effect of D6R amide and D9R amide on anthrax toxemia was studied in RAW264. Inhibitor modeling studies -The crystal structure of mouse furin inhibited with a decanoyl-RVKR-chloromethylketone inhibitor (10) was used for all modeling studies. This structure is also representative of human furin, since all amino acid residues within the active-site cleft are conserved. The (L)-RRRRRRDL -peptide was manually placed into the active-site cleft considering i) the experimentally defined interactions between the P4 through P1 inhibitor side chains with the corresponding S4 through S1 proteinase subsites; ii) the structure of the subtilisin / eglin c complex (15) ; and iii) the subtilisin BPN'-prodomain complex (16) 2) . In all cases we observed that the addition of glutamate was worse for inhibitory potency than the addition of aspartate residue. Furthermore, we observed a slight but significant relationship in that acidic residues added to the carboxy terminus represented more potent inhibitors than those which contained acidic residues on the amino terminus, suggesting that these peptides may indeed favor an orientation in which the acidic residues bind to the positively charged area at the end of the acidic groove, i.e. in the same direction as Lpeptides/substrates. Alternatively, since the difference between (D)-ldrrrrrr and (D)-rrrrrrdl (and the glutamic acid pair) is quite small, it could simply be due to their use of different registries for binding (see below). In summary, the addition of potentially "anchoring" acidic residues did not improve binding ability over the starting compound D6R amide; any change in overall charge did, however, diminish binding affinity.
In order to determine how D-polyarginines bind to the furin substrate binding pocket, we tested modified D6R amide peptides, in which each position was sequentially substituted by either alanine or lysine. Since the furin cleavage consensus sequence is RXR/KR (reviewed in 1), we expected to find D6R amide binding directly into the acidic groove in any position between the S6 and S3' sites. However, as discussed below, the positional scanning library results did not support a specific positioning of D6R amide in the acidic substrate pocket.
Positioning of the hexapeptide from S6 toward the S1 site (S6 S1, see scheme in Figure 2 showing theoretical positioning) was judged to be unlikely because lysine substitution in the (L)-rrrrrk peptide or alanine in the (L)-rrrrra peptide would then be located in the S1 site, which should lead to an unfavorably large increase in K i (this site strictly requires arginine; (1)).
However, as shown in Figure 2 , we observed only slightly increased K i s for these two peptides as compared to (D)-rrrrrr (D6R). S5 S1' positioning also appeared unlikely, because in this case the alanine within the peptide (D)-rrrarr would be located in the S2 site (also known to prefer arginine or lysine), and therefore this positioning would not be associated with the relatively low K i we observed. The S4 S2' positioning of the hexapeptides was also judged unlikely, because the peptide (D)-rrrarr with alanine at the presumed S1 site should be a much worse inhibitor than D6R amide; however, we found that this peptide still exhibited a relatively good K i . Moreover, the very large increase in K i observed with the (D)-rrkrrr peptide (where lysine is placed in the well-accepting S2 site) also should not have been obtained if the peptide is placed in the position S4 S2'.
In the above analysis we assumed that D6R amide is oriented similarly to substrates. Since it is equally possible that the peptides bind in a reverse orientation (see above), we performed a similar analysis for the reverse orientation. This brought us to a similar conclusion, i.e. that no specific positioning is favored. Summarizing, from this experiment we conclude that the various polyarginine-containing peptides most likely do not always bind in the same orientation into the sub-pockets, but may adopt various binding configurations depending on the specific peptide. clearly showed the location of the P5, P6 and P1' and P2' residues in the corresponding subsites (Figure 1 A, B) . The furin residues R193, H364 and R197, located at the border of the S1' pocket provide (in strong contrast to the non-prime subsites) a positive electrostatic surface potential, which should attract negatively charged side chains such as glutamic acid and aspartic acid, in agreement with the known substrate profile of furin. While the P6 to P1 residues remained mostly unchanged during refinement with DISCOVER, the primed-side residues moved slightly away from the surface, obviously due to unfavorable interference with the rigid furin structure (Figure 1B) .
Modeling studies of D-peptides into
Modeling of the D-polyarginine peptides did not reveal a clearly preferred binding geometry.
Upon direct binding, favorable inter-main chain hydrogen bonds remain possible, with most side chains, in particular those of the P1 and the P2 residue, requiring some rearrangement ( Figure   1C ). Upon simple retro binding, all main and side chain atoms in principle can superimpose with the equivalent residues of the experimental L-peptide structure, resulting, however, in the loss of inter-main chain hydrogen bonds and in bad contacts between the P1-carbonyl and the carbonyloxygen of S253 (2.0 A), and the P3-carbonyl and the carbonyl-oxygen of G255 (1.8 A; data not shown). We attempted to relieve these poor contacts by molecular mechanics calculations before ( Figure 1D ) or after ( Figure 1E ) manual flipping of the peptide bonds of the inhibitor. A
comparison of these models with the initial L-peptide model (thin, gray stick models in Figure 1) shows that the three D-peptide models exhibit reasonable binding geometries, with good intermolecular energies of the inhibitor and reasonable interactions between the inhibitor and the enzyme surface. With the D-peptides, however, it is not possible to simultaneously satisfy all side chain and main chain interaction requirements available to the L-peptides. This is in agreement with our experimental results, described below, showing that poly-L-arginines exhibit a higher affinity than poly-D-arginines. Due to the many detailed differences observed, the energies resulting from energy minimization of the D-peptides are not directly comparable. We therefore conclude from our modeling studies that several binding geometries seem to be possible for Dpeptides and that a ranking of these possibilities is not feasible. Polyarginine characterization -It has been previously shown that L9R, even though it can be cleaved by furin, was significantly more potent an inhibitor than both D6R-amide and L6R (7). We therefore tested the inhibitory potency of D-polyarginines of different lengths against human furin. D-peptides were not cleaved by furin (data not shown).
L-and D-decapeptide library scanning -
Similar to previous results obtained using L-peptides (7), an increase in chain length led to a decrease of K i , yielding in the case of D9R-amide the extremely low K i of 1.3 nM ± 0.2 ( Figure   4) . Surprisingly, carboxy-terminal amidation lowered the K i of D6R eight times below that of the unmodified form ( Figure 5) . A detailed examination of the various unmodified and amidated forms of L6R and L9R supported the idea that carboxy-terminal amidation decreases the inhibitory potency of L-peptides but increases it in the case of D-peptides. We also tested the inhibitory potency of other basic peptides. D6K (D-hexalysine) amide did not exhibit inhibitory potency against furin; the K i of this peptide was over 15 µM (data not shown).
We examined also the K i of D6R amide in buffers of different ionic strength. We show that a two-fold increase in ionic strength leads to a two-fold decrease in D6R amide potency ( Table 1 ).
The K m of pERTKR-MCA is simultaneously affected; in buffers of higher ionic strength, the Michaelis constant increased. The calculated K i of D6R amide is lower than 3 nM in a 50 mM buffer, while it increases to over 25 nM in 200 mM HEPES.
The inhibitory effect of D9R was also tested against PC1, PC2, and PACE4. The activity of PC1 and PC2 was not affected by D9R, while the K i of D9R against PACE4 was greater than 25 µM.
Protection of anthrax toxemia by D9R amide in RAW264.7 cells -Previous studies showed
that the D6R amide prevents anthrax toxemia in RAW cells by inhibiting PA cleavage (9).
Because D9R amide exhibited a better K i for furin in enzymatic assays, we tested whether this nonamer is also more potent in blocking anthrax toxemia (Figure 6 ). At every concentration (from 1 µM to 15 µM) D9R amide exhibited improved protection of cells treated with anthrax toxin over D6R amide. We estimated the IC50 to be 3.7 µM. Even at a 1 µM concentration, at which D6R amide was not effective against anthrax toxin, D9R amide treatment resulted in cellular survival of approximately 30%. We also observed that concentrations of D9R amide as high as 250 µM were not toxic (data not shown).
Discussion
In our previous study (7) we found that polyarginine-containing peptides represent potent inhibitors of mouse furin. Since furin is known to take part in activation of several bacterial and viral propeptides or glycoprotein precursors such as the Ebola virus glycoprotein (5), the HIV envelope glycoprotein (6), Pseudomonas aeruginosa exotoxin A (20) , diphtheria toxin (21), and anthrax toxin (2), these inhibitors may have an eventual therapeutic application. The most potent polyarginine-containing peptide previously identified was nona-L-arginine, having a K i of 42 nM (7). The peptide was however cleaved by furin, yielding shorter peptides which still retained inhibitory activity. Interesting was the fact that the unnatural D-form of hexa-arginine was almost as inhibitory as the L-form, having a K i of 106 nM for mouse furin. In the present study we attempted to learn further about the interaction of furin with polyarginine-containing peptides, as well as to possibly identify a more potent inhibitor with a similar structure.
In order to assign relative importance to the different positions within D6R amide, we performed alanine and lysine scans. Our data however indicate that D-arginine-containing peptides most likely do not bind into the substrate-binding pocket in one strictly determined position; each peptide most likely adopts a different distribution among the minimal energy states available.
It is likely that D-polyarginines bind to the furin substrate binding pocket in a reverse manner. This is suggested by the general observation that lysine substitution at any of the first three positions within D6R amide was not well tolerated. The idea that lysine residues are not tolerated near the S1, S1' sites is also supported by the L-decapeptide library scanning results, which showed that lysine is well accepted only in the N-terminal region of the L-peptides studied. The D-decapeptide library data, however, did not show a similar correlation, which might result from the diversified positioning of D-peptides with respect to the S1-S1' subsites.
The fact that amidated D-peptides are more potent than unmodified peptides could also represent an argument for reverse binding, since their non-negatively charged C-termini might exhibit improved binding to the negatively charged non-prime (i.e. from S1 to S6) binding pockets.
On the other hand, with regard to the acidic residue-containing D-polyarginines, these peptides may be oriented normally rather than in a reverse fashion because acidic residues were somewhat better tolerated when placed on the C-terminus (located near a positively charged area within the enzyme). However, since the K i differences between (D)-ldrrrrrr and (D)-rrrrrrdl (and the other pair containing glutamic acid) were quite small, they could simply be due to use of different binding registries. Nonetheless, the modeling studies also seem to suggest the Darginine-containing peptides can bind both in a normal as well as in a reverse manner depending on the particular peptide.
The mechanism of D-polyarginine peptide binding may be mainly based on electrostatic interactions of basic arginines with the negatively charged furin substrate binding groove. This agrees with the observation that higher ionic strength buffers increase the K i of D6R amide.
Reducing the total overall positive charge through the addition of one acidic residue to D6R
amide resulted in a 4-to 7.5-fold increase in the K i . Similarly to previous observations with a hexapeptide library, the positional scanning of the decapeptide libraries (7) showed that basic residues were preferred at all positions. Our data indicate however that charge is not the only element decisive for strong binding into the furin substrate binding pocket, since another basic peptide, D6K amide, exhibited a K i over three orders of magnitude higher than polyarginines.
Similarly we observed that every substitution of D-arginine with D-lysine caused an increase in
A natural inhibitor for furin has not yet been identified, but the presence of potent natural inhibitors for PC1 (proSAAS; (22) ) and PC2 (7B2; (23) ) suggests that such a protein may exist.
The positional scanning library results can be used to search existing protein sequence databases to predict and identify peptide sequences which may potentially interact with furin in vivo. These proteins will be expected to contain an extended highly basic region, a signal peptide, and cellular and tissue distributions consistent with current information on furin.
One of the goals of this study was to identify a more potent polyarginine than D6R amide.
We found that the inhibitory potency of D-polyarginines was directly proportional to 
